查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1662632

2030 年生物製药自动化市场预测：按组件、自动化模式、技术、应用、最终用户和地区进行的全球分析

Automation in Biopharma Market Forecasts to 2030 - Global Analysis By Component, Mode of Automation, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预测期内全球生物製药自动化市场复合年增长率为 8.4%。

生物製药自动化是指利用先进的技术和系统来简化和优化生物製药生产中的各个流程。这包括自动化细胞培养、蛋白质生产、品管、资料分析和包装等任务。透过整合机器人、人工智慧和机器学习，自动化可以提高效率、减少人为错误、提高一致性并缩短新药的上市时间。自动化在确保生物製药行业的法规遵循和成本效益製造方面发挥关键作用。

个人化医疗需求日益增长

个人化医疗的需求不断增长，推动市场需求。个人化治疗，例如基因疗法和客製化生技药品，需要高度专业化和可扩展的製造流程，以满足个别患者的需求。自动化有助于精确控制这些复杂过程，确保一致性和效率。透过提高生产能力并减少人为错误，自动化可以帮助生物製药公司满足日益增长的个人化治疗需求，同时确保高品质标准。

资料安全和隐私问题

生物製药自动化中的资料安全和隐私问题可能导致重大风险，包括未授权存取敏感病患资讯、智慧财产权窃盗和不遵守法规。违规行为可能导致声誉受损、高额罚款以及失去相关人员的信任。资料保护不力也会阻碍创新和协作，因为公司可能不愿意共用关键讯息，最终减缓药物开发并影响市场竞争。

提高资料品质和一致性

提高市场资料的品质和一致性可以改善决策、法规遵循和业务效率。透过整合人工智慧和机器学习等先进技术，企业可以最大限度地减少人为错误，简化资料收集，并确保即时资料的准确性。这将带来更可靠的流程、更快的药物开发和优化的製造——最终缩短上市时间并降低成本，同时保持高品质和安全性。

初期投资成本高

市场上高昂的初始投资成本可能是中小企业面临的一大障碍。先进技术、设备和基础设施的高昂前期成本可能会减缓或阻碍其采用。这可能导致创新放缓、竞争减少和财务压力增加。小型企业可能难以获得融资，从而阻碍其扩大规模、提高效率和跟上行业巨头的能力。

COVID-19 的影响

COVID-19 疫情加速了市场发展，并凸显了对更快、更有效率的药物开发和製造流程的需求。自动化有助于简化疫苗製造、临床测试和供应链管理。然而，疫情扰乱了全球供应链，也导致新技术的采用出现延迟和挑战。儘管存在这些障碍，但这场危机凸显了自动化在增强生物製药业务的弹性和可扩展性方面的作用。

预计预测期内自动化软体部分将实现最大幅度成长。

预计预测期内自动化软体部分将占据最大的市场占有率。整合人工智慧、机器学习和资料分析等技术，以提高效率、减少错误并确保法规符合。透过自动执行重复任务，这些软体解决方案可以提高资料收集的准确性、加快生产进度并支援即时监控。这最终意味着生物製药产业成本降低、产品上市缩短时间、产品品质提升。

预计预测期内製药公司部门将以最高的复合年增长率成长。

预计製药公司部门在预测期内将呈现最高的成长率。整合机器人、人工智慧和机器学习等自动化工具可以提高准确性、减少人为错误并加快生产流程。这些公司专注于优化供应链、临床测试和品管。自动化不仅降低了营运成本，还加速了创新并缩短了关键治疗方法和疗法的上市时间。

比最大的地区

由于技术进步以及对更高效的药物生产和开发流程的需求，预计北美地区将在预测期内占据最大的市场占有率。对人工智慧、机器人和资料分析的大力投资正在帮助北美公司优化製造、加强品管并确保法规合规。该地区注重创新，加上强大的医疗保健基础设施，使其成为生物製药自动化领域的全球领导者。

复合年增长率最高的地区

预计预测期内亚太地区将呈现最高的复合年增长率。对生技药品、生物相似药和先进疗法的需求不断增长，推动生物製药公司采用自动化技术来简化生产流程、提高一致性和规模化生产。此外，先进技术的发展增强了自动化系统，使其更易于生物製药行业使用和适应。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场参与企业（最多 3 家公司）进行全面分析
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球生物製药自动化市场（按组件）

  • 介绍
  • 自动化硬体
  • 自动化软体
  • 服务计划阶段
  • 服务营运阶段
  • 分析自动化
  • 其他的

6. 全球生物製药自动化市场（依自动化模式）

  • 介绍
  • 全自动系统
  • 半自动系统

7. 全球生物製药自动化市场（按技术）

  • 介绍
  • 自动化技术
    • 流程自动化
    • 实验室自动化
    • 机器人和人工智慧
    • 控制系统
    • 可程式逻辑控制器（PLC）
  • 数位化技术
    • 资料分析与视觉化
    • 电子实验室笔记本 (ELN)
    • 云端运算
    • 物联网 (IoT)
    • 数位双胞胎技术

8. 全球生物製药自动化市场（按应用）

  • 介绍
  • 研究与开发
    • 药物研发
    • 基因组学和蛋白​​质组学
  • 生物製造
    • 上游加工
    • 下游加工
  • 实验室测试
  • 品管和保证
  • 诊断
  • 其他的

第九章。

  • 介绍
  • 製药公司
  • 生物製药公司
  • 合约研究组织 (CRO)
  • 学术研究所
  • 诊断实验室
  • 其他的

第 10 章。

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Danaher Corporation
  • GE HealthCare Technologies Inc.
  • PerkinElmer, Inc.
  • Tecan Group Ltd.
  • Sartorius AG
  • Agilent Technologies, Inc.
  • Hamilton Company
  • Bio-Rad Laboratories, Inc.
  • Eppendorf AG
  • Bruker Corporation
  • Honeywell International Inc.
  • Parker Hannifin Corporation
  • Rockwell Automation, Inc.
  • Waters Corporation
  • Yokogawa Electric Corporation
Product Code: SMRC28493

According to Stratistics MRC, the Global Automation in Biopharma Market is growing at a CAGR of 8.4% during the forecast period. Automation in biopharma is the use of advanced technologies and systems to streamline and optimize various processes in the production of biopharmaceuticals. This includes automating tasks such as cell culture, protein production, quality control, data analysis, and packaging. By integrating robotics, artificial intelligence, and machine learning, automation enhances efficiency, reduces human error, improves consistency, and accelerates time-to-market for new drugs. It plays a crucial role in ensuring regulatory compliance and cost-effective manufacturing in the biopharmaceutical industry.

Market Dynamics:

Driver:

Growing demand for personalized medicine

The growing demand for personalized medicine is driving the need for market. Personalized treatments require highly specific and scalable manufacturing processes to cater to individual patient needs, such as gene therapies and customized biologics. Automation facilitates the precise control of these complex processes, ensuring consistency, and efficiency. By enhancing production capabilities and reducing human error, automation enables biopharma companies to meet the increasing demand for tailored therapies, while ensuring high-quality standards.

Restraint:

Data security and privacy concerns

Data security and privacy concerns in biopharma automation can lead to significant risks, including unauthorized access to sensitive patient information, intellectual property theft, and regulatory violations. Breaches may result in reputational damage, costly fines, and loss of trust from stakeholders. Inadequate data protection can also hinder innovation and collaboration, as companies may be reluctant to share critical information, ultimately delaying drug development and affecting market competitiveness.

Opportunity:

Improved data quality and consistency

Improved data quality and consistency in the market enhances decision-making, regulatory compliance, and operational efficiency. By integrating advanced technologies such as AI and machine learning, companies can minimize human errors, streamline data collection, and ensure real-time data accuracy. This leads to more reliable processes, faster drug development, and optimized manufacturing, ultimately accelerating time-to-market and reducing costs while maintaining high standards of quality and safety.

Threat:

High initial investment costs

High initial investment costs in the market can be a significant barrier for smaller companies. The substantial upfront expenses for advanced technologies, equipment, and infrastructure may delay or prevent adoption. This can result in slower innovation, reduced competitiveness, and increased financial pressure. Smaller firms may struggle to secure funding, hindering their ability to scale operations, improve efficiency, and keep pace with larger industry players.

Covid-19 Impact:

The COVID-19 pandemic accelerated the adoption of the market, highlighting the need for faster, more efficient drug development and manufacturing processes. Automation helped streamline vaccine production, clinical trials, and supply chain management. However, the pandemic also disrupted global supply chains, leading to delays and challenges in deploying new technologies. Despite these hurdles, the crisis underscored automation's role in enhancing resilience and scalability in biopharma operations.

The automation software segment is expected to be the largest during the forecast period

The automation software segment is expected to account for the largest market share during the forecast period. It integrates technologies like AI, machine learning, and data analytics to improve efficiency, reduce errors, and ensure regulatory compliance. By automating repetitive tasks, these software solutions enhance accuracy in data collection, speed up production timelines, and support real-time monitoring. This ultimately leads to lower costs, faster time-to-market, and higher product quality in the biopharma industry.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate. By integrating automation tools like robotics, AI, and machine learning, they improve accuracy, reduce human error, and speed up production processes. These companies focus on optimizing supply chains, clinical trials, and quality control. Automation not only lowers operational costs but also accelerates innovation, ensuring faster time-to-market for critical therapies and treatments.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share driven by technological advancements and the need for more efficient drug production and development processes. With strong investments in AI, robotics, and data analytics, North American companies are optimizing manufacturing, enhancing quality control, and ensuring regulatory compliance. The region's focus on innovation, coupled with a robust healthcare infrastructure, positions it as a global leader in biopharma automation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. The growing demand for biologics, biosimilars, and advanced therapies is pushing biopharmaceutical companies to adopt automation technologies to streamline production processes, improve consistency, and meet high production volumes. Additionally, the development of advanced technologies has enhanced automation systems, making them more accessible and adaptable to the biopharmaceutical industry.

Key players in the market

Some of the key players in Automation in Biopharma market include Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, GE HealthCare Technologies Inc., PerkinElmer, Inc., Tecan Group Ltd., Sartorius AG, Agilent Technologies, Inc., Hamilton Company, Bio-Rad Laboratories, Inc., Eppendorf AG, Bruker Corporation, Honeywell International Inc., Parker Hannifin Corporation, Rockwell Automation, Inc., Waters Corporation and Yokogawa Electric Corporation.

Key Developments:

In December 2024, Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. The acquired company will be known as Advanced Accelerator Applications, a Siemens Healthineers company.

In June 2024, Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific(TM) KingFisher(TM) PlasmidPro Maxi Processor* (PlasmidPro), the only fully automated maxi-scale plasmid DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi scale purification and delivering high-purity plasmid without manual column preparation and intervention.

Components Covered:

  • Automation Hardware
  • Automation Software
  • Services Project Phase
  • Services Operation Phase
  • Analytics Automation
  • Other Components

Mode of Automations Covered:

  • Fully Automated Systems
  • Semi-Automated Systems

Technologies Covered:

  • Automation Technology
  • Digitization Technology

Applications Covered:

  • Research & Development
  • Biomanufacturing
  • Clinical Trials
  • Quality Control & Assurance
  • Diagnostics
  • Other Applications

End Users Covered:

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutions
  • Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Automation in Biopharma Market, By Component

  • 5.1 Introduction
  • 5.2 Automation Hardware
  • 5.3 Automation Software
  • 5.4 Services Project Phase
  • 5.5 Services Operation Phase
  • 5.6 Analytics Automation
  • 5.7 Other Components

6 Global Automation in Biopharma Market, By Mode of Automation

  • 6.1 Introduction
  • 6.2 Fully Automated Systems
  • 6.3 Semi-Automated Systems

7 Global Automation in Biopharma Market, By Technology

  • 7.1 Introduction
  • 7.2 Automation Technology
    • 7.2.1 Process Automation
    • 7.2.2 Laboratory Automation
    • 7.2.3 Robotics and Artificial Intelligence
    • 7.2.4 Control Systems
    • 7.2.5 Programmable Logic Controllers (PLCs)
  • 7.3 Digitization Technology
    • 7.3.1 Data Analytics and Visualization
    • 7.3.2 Electronic Lab Notebooks (ELN)
    • 7.3.3 Cloud Computing
    • 7.3.4 Internet of Things (IoT)
    • 7.3.5 Digital Twin Technology

8 Global Automation in Biopharma Market, By Application

  • 8.1 Introduction
  • 8.2 Research & Development
    • 8.2.1 Drug Discovery
    • 8.2.2 Genomics and Proteomics
  • 8.3 Biomanufacturing
    • 8.3.1 Upstream Processing
    • 8.3.2 Downstream Processing
  • 8.4 Clinical Trials
  • 8.5 Quality Control & Assurance
  • 8.6 Diagnostics
  • 8.7 Other Applications

9 Global Automation in Biopharma Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
  • 9.3 Biopharmaceutical Companies
  • 9.4 Contract Research Organizations (CROs)
  • 9.5 Academic and Research Institutions
  • 9.6 Diagnostic Laboratories
  • 9.7 Other End Users

10 Global Automation in Biopharma Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 Siemens Healthineers AG
  • 12.3 Danaher Corporation
  • 12.4 GE HealthCare Technologies Inc.
  • 12.5 PerkinElmer, Inc.
  • 12.6 Tecan Group Ltd.
  • 12.7 Sartorius AG
  • 12.8 Agilent Technologies, Inc.
  • 12.9 Hamilton Company
  • 12.10 Bio-Rad Laboratories, Inc.
  • 12.11 Eppendorf AG
  • 12.12 Bruker Corporation
  • 12.13 Honeywell International Inc.
  • 12.14 Parker Hannifin Corporation
  • 12.15 Rockwell Automation, Inc.
  • 12.16 Waters Corporation
  • 12.17 Yokogawa Electric Corporation

List of Tables

  • Table 1 Global Automation in Biopharma Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Automation in Biopharma Market Outlook, By Component (2022-2030) ($MN)
  • Table 3 Global Automation in Biopharma Market Outlook, By Automation Hardware (2022-2030) ($MN)
  • Table 4 Global Automation in Biopharma Market Outlook, By Automation Software (2022-2030) ($MN)
  • Table 5 Global Automation in Biopharma Market Outlook, By Services Project Phase (2022-2030) ($MN)
  • Table 6 Global Automation in Biopharma Market Outlook, By Services Operation Phase (2022-2030) ($MN)
  • Table 7 Global Automation in Biopharma Market Outlook, By Analytics Automation (2022-2030) ($MN)
  • Table 8 Global Automation in Biopharma Market Outlook, By Other Components (2022-2030) ($MN)
  • Table 9 Global Automation in Biopharma Market Outlook, By Mode of Automation (2022-2030) ($MN)
  • Table 10 Global Automation in Biopharma Market Outlook, By Fully Automated Systems (2022-2030) ($MN)
  • Table 11 Global Automation in Biopharma Market Outlook, By Semi-Automated Systems (2022-2030) ($MN)
  • Table 12 Global Automation in Biopharma Market Outlook, By Technology (2022-2030) ($MN)
  • Table 13 Global Automation in Biopharma Market Outlook, By Automation Technology (2022-2030) ($MN)
  • Table 14 Global Automation in Biopharma Market Outlook, By Process Automation (2022-2030) ($MN)
  • Table 15 Global Automation in Biopharma Market Outlook, By Laboratory Automation (2022-2030) ($MN)
  • Table 16 Global Automation in Biopharma Market Outlook, By Robotics and Artificial Intelligence (2022-2030) ($MN)
  • Table 17 Global Automation in Biopharma Market Outlook, By Control Systems (2022-2030) ($MN)
  • Table 18 Global Automation in Biopharma Market Outlook, By Programmable Logic Controllers (PLCs) (2022-2030) ($MN)
  • Table 19 Global Automation in Biopharma Market Outlook, By Digitization Technology (2022-2030) ($MN)
  • Table 20 Global Automation in Biopharma Market Outlook, By Data Analytics and Visualization (2022-2030) ($MN)
  • Table 21 Global Automation in Biopharma Market Outlook, By Electronic Lab Notebooks (ELN) (2022-2030) ($MN)
  • Table 22 Global Automation in Biopharma Market Outlook, By Cloud Computing (2022-2030) ($MN)
  • Table 23 Global Automation in Biopharma Market Outlook, By Internet of Things (IoT) (2022-2030) ($MN)
  • Table 24 Global Automation in Biopharma Market Outlook, By Digital Twin Technology (2022-2030) ($MN)
  • Table 25 Global Automation in Biopharma Market Outlook, By Application (2022-2030) ($MN)
  • Table 26 Global Automation in Biopharma Market Outlook, By Research & Development (2022-2030) ($MN)
  • Table 27 Global Automation in Biopharma Market Outlook, By Drug Discovery (2022-2030) ($MN)
  • Table 28 Global Automation in Biopharma Market Outlook, By Genomics and Proteomics (2022-2030) ($MN)
  • Table 29 Global Automation in Biopharma Market Outlook, By Biomanufacturing (2022-2030) ($MN)
  • Table 30 Global Automation in Biopharma Market Outlook, By Upstream Processing (2022-2030) ($MN)
  • Table 31 Global Automation in Biopharma Market Outlook, By Downstream Processing (2022-2030) ($MN)
  • Table 32 Global Automation in Biopharma Market Outlook, By Clinical Trials (2022-2030) ($MN)
  • Table 33 Global Automation in Biopharma Market Outlook, By Quality Control & Assurance (2022-2030) ($MN)
  • Table 34 Global Automation in Biopharma Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 35 Global Automation in Biopharma Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 36 Global Automation in Biopharma Market Outlook, By End User (2022-2030) ($MN)
  • Table 37 Global Automation in Biopharma Market Outlook, By Pharmaceutical Companies (2022-2030) ($MN)
  • Table 38 Global Automation in Biopharma Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 39 Global Automation in Biopharma Market Outlook, By Contract Research Organizations (CROs) (2022-2030) ($MN)
  • Table 40 Global Automation in Biopharma Market Outlook, By Academic and Research Institutions (2022-2030) ($MN)
  • Table 41 Global Automation in Biopharma Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 42 Global Automation in Biopharma Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.